Administer: Steadily towards growth - Evli
Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.
Administer reports Q2 on August 14. We expect net sales and profitability to remain broadly flat y/y, with market conditions still difficult and no contribution yet from the pending Sarastia acquisition, which is awaiting regulatory approval.